LAKE ZURICH, Ill.–(BUSINESS WIRE)–The United States District Court for the District of Massachusetts has
granted Fenwal’s motions for summary judgment in two related patent
lawsuits brought by Haemonetics Corporation in 2005 and 2009. In its
ruling, the court held that the Fenwal Alyx® system kits do
not infringe the Haemonetics patent.
“We respect the intellectual property of other companies and have said
from the beginning that these suits have no merit”
A link to the Memorandum & Order, filed on September 13, 2011, can be
found at www.fenwalinc.com.
The decision is consistent with the June 2010 ruling in favor of Fenwal
by the United States Court of Appeals for the Federal Circuit.
At issue was a centrifugal component of the Fenwal Alyx® system
kit, which blood centers and hospitals use to collect red blood cells.
“We respect the intellectual property of other companies and have said
from the beginning that these suits have no merit,” said Dean Gregory,
Fenwal senior vice president, Commercial Operations. “Most of all, this
is a victory for our customers who have supported us for years as we
worked to ensure these lawsuits wouldn’t disrupt their operations.”
About Fenwal
Fenwal, Inc. is a global medical technology company focused on improving
blood collection, filtration, separation, storage and transfusion to
ensure the availability, safety and effectiveness of blood components.
Fenwal is unique in the depth of its experience and commitment to
transfusion medicine. The company offers a broad range of products for
the automated and manual collection of blood and blood components.
Fenwal products and advanced collection and separation technologies are
used to help treat patients on six continents. Fenwal, Inc. is based in
Lake Zurich, Illinois. For more information about Fenwal, please visit www.fenwalinc.com.